688321 微芯生物
已收盘 08-21 15:00:01
资讯
新帖
简况
微芯生物：8月20日进行路演，东吴证券、招商证券等多家机构参与
证券之星 · 08-21 18:29
微芯生物：8月20日进行路演，东吴证券、招商证券等多家机构参与
微芯生物（688321）2026年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 08-21 06:07
微芯生物（688321）2026年中报简析：营收净利润同比双双增长，应收账款上升
图解微芯生物中报：第二季度单季净利润同比下降11.57%
证券之星 · 08-20 01:13
图解微芯生物中报：第二季度单季净利润同比下降11.57%
微芯生物(688321.SH)发布半年度业绩，归母净利润7138.06万元，同比增长141.21%
智通财经 · 08-19 19:28
微芯生物(688321.SH)发布半年度业绩，归母净利润7138.06万元，同比增长141.21%
微芯生物(688321)6月30日股东户数2.56万户，较上期减少2.72%
证券之星 · 08-19 18:02
微芯生物(688321)6月30日股东户数2.56万户，较上期减少2.72%
每周股票复盘：微芯生物（688321）将召开2026年半年度业绩说明会
证券之星 · 08-16
每周股票复盘：微芯生物（688321）将召开2026年半年度业绩说明会
股市必读：微芯生物新发布《关于召开2026年半年度业绩说明会的公告》
证券之星 · 08-14
股市必读：微芯生物新发布《关于召开2026年半年度业绩说明会的公告》
微芯生物（688321）披露2026年半年度业绩说明会召开安排，8月12日股价上涨0.03%
证券之星 · 08-12
微芯生物（688321）披露2026年半年度业绩说明会召开安排，8月12日股价上涨0.03%
8月7日微芯生物涨9.74%，建信中证1000指数增强A基金重仓该股
证券之星 · 08-07
8月7日微芯生物涨9.74%，建信中证1000指数增强A基金重仓该股
股市必读：微芯生物新发布《深圳微芯生物科技股份有限公司董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予及预留授予（第一批次）部分激励对象名单的核查意见》
证券之星 · 08-06
股市必读：微芯生物新发布《深圳微芯生物科技股份有限公司董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予及预留授予（第一批次）部分激励对象名单的核查意见》
微芯生物最新公告：注射用NW001临床试验申请获国家药监局受理
证券之星 · 08-05
微芯生物最新公告：注射用NW001临床试验申请获国家药监局受理
微芯生物（688321）披露向2026年限制性股票激励计划激励对象首次及预留部分（第一批次）授予限制性股票的公告，8月4日股价上涨3.74%
证券之星 · 08-04
微芯生物（688321）披露向2026年限制性股票激励计划激励对象首次及预留部分（第一批次）授予限制性股票的公告，8月4日股价上涨3.74%
股市必读：微芯生物新发布《自愿披露关于CS43158片临床试验申请获得受理的公告》
证券之星 · 08-03
股市必读：微芯生物新发布《自愿披露关于CS43158片临床试验申请获得受理的公告》
【机构调研记录】建信基金调研微芯生物、翔丰华
证券之星 · 07-31
【机构调研记录】建信基金调研微芯生物、翔丰华
【机构调研记录】华夏基金调研科士达、微芯生物
证券之星 · 07-31
【机构调研记录】华夏基金调研科士达、微芯生物
【私募调研记录】高毅资产调研云天化、微芯生物
证券之星 · 07-31
【私募调研记录】高毅资产调研云天化、微芯生物
微芯生物（688321）披露CS43158片临床试验申请获得受理的公告，7月30日股价下跌5.33%
证券之星 · 07-30
微芯生物（688321）披露CS43158片临床试验申请获得受理的公告，7月30日股价下跌5.33%
微芯生物最新公告：CS43158片临床试验申请获受理
证券之星 · 07-30
微芯生物最新公告：CS43158片临床试验申请获受理
7月30日微芯生物跌5.33%，建信中证1000指数增强A基金重仓该股
证券之星 · 07-30
7月30日微芯生物跌5.33%，建信中证1000指数增强A基金重仓该股
7月28日微芯生物跌5.16%，建信中证1000指数增强A基金重仓该股
证券之星 · 07-28
7月28日微芯生物跌5.16%，建信中证1000指数增强A基金重仓该股
加载更多
公司概况
公司名称：
深圳微芯生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2019-08-12
主营业务：
深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用；新药研究、开发、技术转让及其它有关的服务；新治疗技术研究、开发、技术转让及其它有关的服务；对外专利、技术的许可授权；药品的生产；保健食品生产经营。公司的主要产品是西达本胺、西格列他钠、西奥罗尼、CS23546、CS231295、CS32582、CS08399、CS43158、NW001、CS12088、CS12192。公司是国家级专精特新“小巨人”企业。
发行价格：
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":27.95,"timestamp":1787295601000,"preClose":29.95,"halted":0,"volume":20890261,"delay":0,"changeRate":-0.0668,"floatShares":408000000,"shares":443000000,"eps":0.2094,"marketStatus":"已收盘","change":-2,"latestTime":"08-21 15:00:01","open":29.59,"high":29.95,"low":27.83,"amount":595000000,"amplitude":0.0708,"askPrice":27.96,"askSize":124,"bidPrice":27.95,"bidSize":77,"shortable":0,"etf":0,"ttmEps":0.2094,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":5,"adr":0,"adjPreClose":29.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":32.95,"lowLimit":26.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":442941287,"isCdr":false,"pbRate":5.1,"roa":"--","peRate":133.4766,"roe":"3.14%","epsLYR":0.125,"committee":0.688266,"marketValue":12380000000,"turnoverRate":0.0512,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-08-24。","afterMarket":{"amount":69875,"volume":2500,"close":27.95,"buyVolume":6146,"sellVolume":0,"time":1787297637746,"indexStatus":"已收盘 08-21 15:30:00","preClose":29.95},"floatMarketCap":11398000000},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2661426420","title":"微芯生物：8月20日进行路演，东吴证券、招商证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2661426420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661426420?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:29","pubTimestamp":1787308188,"startTime":"0","endTime":"0","summary":"公司与HUYBIO将根据已签订的协议约定进行西达本胺相关的商业收入分成，如后续触发相关节点，公司将及时进行信息披露。答：NW001已于8月5日收到IND受理通知书，如无意外，预计60个工作日后即可默许启动临床试验。该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100034679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0012","BK1147","06099","BK0028","BK1564","BK0239","BK0188","BK0276","600999","601555","BK0183","BK0010","BK0009"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661963230","title":"微芯生物（688321）2026年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2661963230","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661963230?lang=zh_cn&edition=full","pubTime":"2026-08-21 06:07","pubTimestamp":1787263657,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期微芯生物发布2026年中报。截至本报告期末，公司营业总收入5.43亿元，同比上升33.6%，归母净利润7138.06万元，同比上升141.21%。本报告期微芯生物应收账款上升，应收账款同比增幅达50.37%。合同负债变动幅度为483.81%,原因:报告期预收服务费增加。管理费用变动幅度为1.22%,原因:营业收入增长下，管理费用整体保持稳定。针对特定基因突变的患者也有一些靶向药物获批上市。本文数据来源于微芯生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100004755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660242276","title":"图解微芯生物中报：第二季度单季净利润同比下降11.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660242276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660242276?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:13","pubTimestamp":1787159599,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物2026年中报显示，上半年度公司主营收入5.43亿元，同比上升33.6%；归母净利润7138.06万元，同比上升141.21%；扣非净利润6470.18万元，同比上升218.41%；其中2026年第二季度，公司单季度主营收入2.86亿元，同比上升17.13%；单季度归母净利润4310.87万元，同比下降11.57%；单季度扣非净利润3905.77万元，同比下降13.02%；负债率44.56%，投资收益-1400.54万元，财务费用1678.42万元，毛利率86.33%。财报数据概要请见下图:本文数据来源于微芯生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440505","title":"微芯生物(688321.SH)发布半年度业绩，归母净利润7138.06万元，同比增长141.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440505","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660440505?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:28","pubTimestamp":1787138926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)披露2026年半年度报告，报告期公司实现营业收入5.43亿元，同比增长33.60%;归属于上市公司股东的净利润7138.06万元，同比增长141.21%;扣除非经常性损益的净利润6470.18万元，同比增长218.41%;基本每股收益0.1645元。报告期内，公司产品西格列他钠较去年上半年保持翻倍以上增长，且其八车间两条固体制剂生产线已于第二季度获得药品GMP符合性检查告知书，为下半年产能提供有力支撑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微芯生物(688321.SH)发布半年度业绩，归母净利润7138.06万元，同比增长141.21%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660744441","title":"微芯生物(688321)6月30日股东户数2.56万户，较上期减少2.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660744441","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660744441?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133755,"startTime":"0","endTime":"0","summary":"证券之星消息，近日微芯生物披露，截至2026年6月30日公司股东户数为2.56万户，较3月31日减少716.0户，减幅为2.72%。在化学制药行业个股中，微芯生物股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.64万户。从股价来看，2026年3月31日至2026年6月30日，微芯生物区间跌幅为7.66%，在此期间股东户数减少716.0户，减幅为2.72%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659671175","title":"每周股票复盘：微芯生物（688321）将召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2659671175","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659671175?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:32","pubTimestamp":1786815129,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，微芯生物报收于30.85元，较上周的29.74元上涨3.73%。本周，微芯生物8月13日盘中最高价报32.15元。8月10日盘中最低价报28.92元。微芯生物当前最新总市值136.65亿元，在化学制药板块市值排名35/149，在两市A股市值排名1397/5207。本周关注点公司公告汇总：微芯生物将于2026年8月20日召开半年度业绩说明会，介绍经营成果及财务状况。投资者可于2026年8月13日至8月19日16:00前通过上证路演中心网站或公司邮箱ir@chipscreen.com提交问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659611169","title":"股市必读：微芯生物新发布《关于召开2026年半年度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659611169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659611169?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:09","pubTimestamp":1786640952,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，微芯生物报收于31.17元，上涨1.73%，换手率4.69%，成交量19.12万手，成交额5.98亿元。公司公告汇总：微芯生物将于2026年8月20日召开2026年半年度业绩说明会，投资者可于8月13日至19日16:00前提交问题。公司公告汇总关于召开2026年半年度业绩说明会的公告深圳微芯生物科技股份有限公司将于2026年8月20日10:00-11:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司半年度经营成果及财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658905348","title":"微芯生物（688321）披露2026年半年度业绩说明会召开安排，8月12日股价上涨0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658905348","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658905348?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:25","pubTimestamp":1786544718,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，微芯生物报收于30.64元，较前一交易日上涨0.03%，最新总市值为135.72亿元。该股当日开盘30.3元，最高31.17元，最低30.15元，成交额达4.38亿元，换手率为3.49%。公司将于2026年8月20日10:00-11:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司半年度经营成果及财务状况。投资者可于2026年8月13日至8月19日16:00前通过上证路演中心网站或公司邮箱ir@chipscreen.com提交问题。说明会结束后可通过该平台查看会议内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657816616","title":"8月7日微芯生物涨9.74%，建信中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657816616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657816616?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:41","pubTimestamp":1786092101,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日微芯生物涨9.74%，收盘报29.74元，换手率6.12%，成交量24.97万手，成交额7.18亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为建信基金的建信中证1000指数增强A。建信中证1000指数增强A目前规模为8.27亿元，最新净值2.1327，较上一交易日上涨0.73%，近一年上涨17.79%。建信中证1000指数增强A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657248475","title":"股市必读：微芯生物新发布《深圳微芯生物科技股份有限公司董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予及预留授予（第一批次）部分激励对象名单的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657248475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657248475?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:59","pubTimestamp":1785952764,"startTime":"0","endTime":"0","summary":"深圳微芯生物科技股份有限公司2026年限制性股票激励计划首次授予及预留授予部分激励对象名单本次授予权益总数为7,087,061股，其中首次授予6,846,000股，涉及177名激励对象；预留部分241,061股；实际控制人XIANPING LU获授4,429,000股；所有激励对象获授股票均未超过公司股本总额的1.00%，累计标的股票总数未超过公司股本总额的20.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545844","title":"微芯生物最新公告：注射用NW001临床试验申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545844","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657545844?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:40","pubTimestamp":1785926437,"startTime":"0","endTime":"0","summary":"微芯生物(688321.SH)公告称，公司与成都微芯新域生物技术有限公司合作研发的注射用NW001关于治疗晚期恶性肿瘤(实体瘤和淋巴瘤)的临床试验申请获得国家药监局药审中心受理。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500036726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656529745","title":"微芯生物（688321）披露向2026年限制性股票激励计划激励对象首次及预留部分（第一批次）授予限制性股票的公告，8月4日股价上涨3.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656529745","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656529745?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:30","pubTimestamp":1785853839,"startTime":"0","endTime":"0","summary":"近日，深圳微芯生物科技股份有限公司披露《关于向2026年限制性股票激励计划激励对象首次及预留部分授予限制性股票的公告》。公告显示，公司于2026年8月4日向177名激励对象首次授予6,846,000股限制性股票，向11名激励对象授予预留部分75,000股限制性股票，授予价格为15.54元/股。本次授予的限制性股票归属期分别为自授予日起12个月后分两批归属，每批归属比例均为50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656348224","title":"股市必读：微芯生物新发布《自愿披露关于CS43158片临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656348224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656348224?lang=zh_cn&edition=full","pubTime":"2026-08-03 01:48","pubTimestamp":1785692894,"startTime":"0","endTime":"0","summary":"公司公告汇总自愿披露关于CS43158片临床试验申请获得受理的公告深圳微芯生物科技股份有限公司近日收到国家药品监督管理局药物审评中心签发的《受理通知书》，公司自主研发的CS43158片用于治疗急性髓系白血病的新药临床试验申请已获受理，受理号为CXHL2600937、CXHL2600938，受理日期为2026年7月30日。本次申请为新药临床试验申请，自受理之日起60日内若无否定或质疑意见，公司可按方案开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655387879","title":"【机构调研记录】建信基金调研微芯生物、翔丰华","url":"https://stock-news.laohu8.com/highlight/detail?id=2655387879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655387879?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:04","pubTimestamp":1785456273,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及7月30日披露的机构调研信息，建信基金近期对2家上市公司进行了调研，相关名单如下：1）微芯生物 调研纪要：西达本胺联合纳武利尤单抗一线治疗黑色素瘤全球III期临床成功，mPFS达11.7个月，为当前最高值，并在脑转移人群中展现良好疗效。旗下最近一年表现最佳的公募基金产品为建信电子行业股票A，最新单位净值为2.43，近一年增长84.15%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100006500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321","BK0235","300890"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655038732","title":"【机构调研记录】华夏基金调研科士达、微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2655038732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655038732?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:04","pubTimestamp":1785456263,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及7月30日披露的机构调研信息，华夏基金近期对2家上市公司进行了调研，相关名单如下：1）科士达 调研纪要：公司依托长期电力电子技术积累布局IDC市场，大功率UPS等成熟产品已实现海内外稳定供货，新一代产品如兆瓦级UPS、800V HVDC等正处于验证导入阶段。2030年全球黑色素瘤药物市场预计达72亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100006481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","688321","002518","BK0224","BK0054","BK0156","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655938734","title":"【私募调研记录】高毅资产调研云天化、微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2655938734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655938734?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:04","pubTimestamp":1785456250,"startTime":"0","endTime":"0","summary":"2）微芯生物 调研纪要：西达本胺联合纳武利尤单抗一线治疗黑色素瘤全球III期临床成功，mPFS达11.7个月，为当前最高值，并在脑转移人群中展现良好疗效。2030年全球黑色素瘤药物市场预计达72亿美元。高毅资产旗下汇聚了多位长期业绩优秀、市场经验丰富的明星投资经理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026073100006457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","BK0229","LU0469268626.HKD","600096","BK0239","688321","BK0188","LU1979443071.USD","BK0044"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655580517","title":"微芯生物（688321）披露CS43158片临床试验申请获得受理的公告，7月30日股价下跌5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655580517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655580517?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:14","pubTimestamp":1785420857,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，微芯生物报收于25.95元，较前一交易日下跌5.33%，最新总市值为114.94亿元。微芯生物近日收到国家药品监督管理局药物审评中心签发的《受理通知书》，公司自主研发的CS43158片用于治疗急性髓系白血病的新药临床试验申请已获受理，受理号为CXHL2600937、CXHL2600938，受理日期为2026年7月30日。本次申请为新药临床试验申请，自受理之日起60日内若无否定或质疑意见，公司可按方案开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655875652","title":"微芯生物最新公告：CS43158片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655875652","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655875652?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:40","pubTimestamp":1785408011,"startTime":"0","endTime":"0","summary":"微芯生物(688321.SH)公告称，公司近日收到国家药监局药审中心签发的《受理通知书》，自主研发的CS43158片用于治疗急性髓系白血病的临床试验申请获得受理。CS43158是一款多靶点蛋白激酶抑制剂，可同时覆盖急性髓系白血病（AML）的驱动致癌通路与旁路激活耐药通路，兼具靶向原发驱动突变与克服继发耐药的双重作用。临床试验能否最终开展存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000031980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655922824","title":"7月30日微芯生物跌5.33%，建信中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655922824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655922824?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:41","pubTimestamp":1785400885,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日微芯生物跌5.33%，收盘报25.95元，换手率2.79%，成交量11.36万手，成交额3.01亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为建信基金的建信中证1000指数增强A。建信中证1000指数增强A目前规模为8.27亿元，最新净值2.0089，较上一交易日上涨0.61%，近一年上涨13.52%。建信中证1000指数增强A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000025982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654077355","title":"7月28日微芯生物跌5.16%，建信中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654077355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654077355?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:44","pubTimestamp":1785228270,"startTime":"0","endTime":"0","summary":"证券之星消息，7月28日微芯生物跌5.16%，收盘报27.18元，换手率3.32%，成交量13.53万手，成交额3.73亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为建信基金的建信中证1000指数增强A。建信中证1000指数增强A目前规模为8.27亿元，最新净值2.064，较上一交易日上涨2.86%，近一年上涨17.55%。建信中证1000指数增强A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787364433998,"stockEarnings":[{"period":"1week","weight":-0.094},{"period":"1month","weight":-0.0605},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.1202},{"period":"1year","weight":-0.2598},{"period":"ytd","weight":-0.0417}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0433},{"period":"1year","weight":0.0356},{"period":"ytd","weight":-0.016}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25565人(较上一季度减少2.72%)","perCapita":"15951股","listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","registeredCapital":"44294万元","survey":" 深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用；新药研究、开发、技术转让及其它有关的服务；新治疗技术研究、开发、技术转让及其它有关的服务；对外专利、技术的许可授权；药品的生产；保健食品生产经营。公司的主要产品是西达本胺、西格列他钠、西奥罗尼、CS23546、CS231295、CS32582、CS08399、CS43158、NW001、CS12088、CS12192。公司是国家级专精特新“小巨人”企业。","listedPrice":20.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}